2021 Annual Meeting - Difficult Cases in Small Cell Lung Cancer

Radiation is an integral component of the treatment of small cell lung cancer, as a definitive treatment for limited stage disease, as prophylactic cranial irradiation for prevention of brain metastases, as consolidation to the chest in extensive stage disease, and for palliation. However, recent developments in small cell lung cancer have created areas of ongoing debate. This panel session will review three challenging cases in the contemporary management of small cell lung cancer. Case 1 will be a patient with early stage, node negative small cell lung cancer. The panel will review the available data for surgery and SABR in this setting, and the role (or lack thereof) for PCI for node negative SCLC. The second case will be a patient with extensive stage disease, treated with first-line chemo-immunotherapy. The panel will review the data for consolidative thoracic radiation following chemotherapy, and the current guidance for consolidative thoracic RT in the setting of first-line chemo-immunotherapy. The panel will also review the current status of PCI for extensive stage small cell lung cancer. Case 3 will review a patient with a solitary brain metastasis from small cell lung cancer. The panel will review the data for use of SRS versus whole brain RT for limited or single brain metastases from small cell lung cancer, and more generally the management of SCLC brain metastases. The panel will include 3 radiation oncologists and a medical oncologist. 

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, specialists and medical oncologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine an evidence-based treatment approach for small cell lung cancer patients with early stage, node negative disease.
  • Discuss the data addressing the use of prophylactic cranial irradiation for small cell lung cancer and perform shared decision making with patients undergoing consideration for PCI for SCLC.
  • Develop an evidence-based treatment plan for patients with brain metastases from small cell lung cancer.
Course summary
Available credit: 
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
  • 1.25 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.

Course opens: 
08/23/2021
Course expires: 
11/30/2021
Cost:
$0.00
Rating: 
0
  • Megan E Daly, MD, University of California, Davis and receives compensation from Merck, EMD Serono, Genetech, Department of Defense and NIH. 
  • Jyoti D. Patel, MD, Lurie Cancer Center, Northwestern University Feinberg School of Medicine and receives compensation from AbbVie, AstraZeneca, BMS and Takeda.
  • Dawn Owen, MD, PhD, Department of Radiation Oncology, Mayo Clinic and  receives compensation from Mayo Clinic and NIH. 
  • Chad G. Rusthoven Jr, MD, Department of Radiation Oncology, University of Colorado School of Medicine and  receives compensation from Takeda.

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
  • 1.25 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.

Price

Cost:
$0.00
Please login or register to take this course.

Policies: 
    • No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
    • No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
    • ASTRO staff cannot make modifications to your submitted materials.
 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.